CL2023001735A1 - Moléculas bifuncionales novedosas para la degradación de proteínas dirigidas - Google Patents

Moléculas bifuncionales novedosas para la degradación de proteínas dirigidas

Info

Publication number
CL2023001735A1
CL2023001735A1 CL2023001735A CL2023001735A CL2023001735A1 CL 2023001735 A1 CL2023001735 A1 CL 2023001735A1 CL 2023001735 A CL2023001735 A CL 2023001735A CL 2023001735 A CL2023001735 A CL 2023001735A CL 2023001735 A1 CL2023001735 A1 CL 2023001735A1
Authority
CL
Chile
Prior art keywords
bifunctional molecules
protein degradation
targeted protein
novel bifunctional
targeted
Prior art date
Application number
CL2023001735A
Other languages
English (en)
Inventor
Andrea Testa
Callum Macgregor
David Mcgarry
Gregor Meier
Ian Churcher
Michael Mathieson
Original Assignee
Amphista Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2020186.9A external-priority patent/GB202020186D0/en
Priority claimed from GBGB2102494.8A external-priority patent/GB202102494D0/en
Application filed by Amphista Therapeutics Ltd filed Critical Amphista Therapeutics Ltd
Publication of CL2023001735A1 publication Critical patent/CL2023001735A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se refiere a una nueva clase de moléculas bifuncionales que son útiles en una degradación dirigida o selectiva de una proteína.
CL2023001735A 2020-12-18 2023-06-14 Moléculas bifuncionales novedosas para la degradación de proteínas dirigidas CL2023001735A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2020186.9A GB202020186D0 (en) 2020-12-18 2020-12-18 Novel bifunctional molecules for targeted protein degradation
GBGB2102494.8A GB202102494D0 (en) 2021-02-22 2021-02-22 Novel bifunctional molecules for targeted protein degredation

Publications (1)

Publication Number Publication Date
CL2023001735A1 true CL2023001735A1 (es) 2024-02-16

Family

ID=79164461

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001735A CL2023001735A1 (es) 2020-12-18 2023-06-14 Moléculas bifuncionales novedosas para la degradación de proteínas dirigidas

Country Status (12)

Country Link
US (1) US20240115711A1 (es)
EP (1) EP4263511A1 (es)
JP (1) JP2024505328A (es)
KR (1) KR20230137889A (es)
AU (1) AU2021400059A1 (es)
CA (1) CA3201962A1 (es)
CL (1) CL2023001735A1 (es)
CO (1) CO2023007768A2 (es)
IL (1) IL303717A (es)
MX (1) MX2023007032A (es)
PE (1) PE20240545A1 (es)
WO (1) WO2022129925A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023242598A1 (en) 2022-06-16 2023-12-21 Amphista Therapeutics Limited Bifunctional molecules for targeted protein degradation
WO2023242597A1 (en) 2022-06-16 2023-12-21 Amphista Therapeutics Limited Bifunctional molecules for targeted protein degradation
WO2024057021A1 (en) 2022-09-13 2024-03-21 Amphista Therapeutics Limited Compounds for targeted protein degradation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012237A1 (fr) * 1990-02-08 1991-08-22 Eisai Co., Ltd. Derive de sulfonamide de benzene
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
AU2005229522A1 (en) * 2004-03-11 2005-10-13 Actelion Pharmaceuticals Ltd. Indol-1-yl-acetic acid derivatives
RU59063U1 (ru) 2006-05-30 2006-12-10 Государственное образовательное учреждение высшего профессионального образования "Ульяновский государственный технический университет" Режущий инструмент с многослойным покрытием
WO2012078559A2 (en) 2010-12-07 2012-06-14 Yale University Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
TW201444836A (zh) 2013-03-14 2014-12-01 Abbvie Inc 吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑
WO2014210354A1 (en) 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
HUE061599T2 (hu) 2017-11-15 2023-07-28 Mirati Therapeutics Inc KRas G12C inhibotorok
WO2019238886A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting usp14
CA3103185A1 (en) 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting rpn11
US20210283139A1 (en) 2018-06-13 2021-09-16 Amphista Therapeutics Ltd Bifunctional molecules for targeting uchl5

Also Published As

Publication number Publication date
JP2024505328A (ja) 2024-02-06
MX2023007032A (es) 2023-07-18
PE20240545A1 (es) 2024-03-19
KR20230137889A (ko) 2023-10-05
AU2021400059A1 (en) 2023-07-06
CA3201962A1 (en) 2022-06-23
WO2022129925A1 (en) 2022-06-23
IL303717A (en) 2023-08-01
CO2023007768A2 (es) 2023-09-29
US20240115711A1 (en) 2024-04-11
EP4263511A1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
CO2023007768A2 (es) Moléculas bifuncionales novedosas para la degradación de proteínas dirigidas
AR111184A1 (es) Poliamidas y métodos para producir los mismos
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CY1125025T1 (el) 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
CL2021001690S1 (es) Estuche para audífonos.
CO2019009258A2 (es) Administración rápida y controlada de composiciones con efectos séquito restaurados
CO2020005981A2 (es) Anticuerpos anti-tau y uso de los mismos
CO2019002239A2 (es) Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados
CL2021003039A1 (es) Moléculas de unión a tigit y pd-1/tigit
ECSP099688A (es) Moléculas y métodos para modular la pro-proteína
AR078858A1 (es) Proteinas encapsulantes de lipidos neutros modificadas y sus usos
CO2020005349A2 (es) Composiciones de hierbas con mejor biodisponibilidad
PE20151774A1 (es) Construcciones de proteinas mitocondriales y sus usos
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
CU20210096A7 (es) Moléculas de unión a cd19
BR112018004310A2 (pt) derivados de espinosina e método de preparação
CL2020002052A1 (es) Composiciones de edb que se dirigen a il-12.
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
ECSP23073436A (es) Anticuerpos anti-nectina-4 y usos de los mismos
CO2020001107A2 (es) Moduladores terapéuticos del modo inverso de la atp sintasa
PL432733A1 (pl) Transgeniczny rekin tęczowy
CL2020000586A1 (es) Moduladores de la expresión de enac.
UY39337A (es) Anticuerpos anti-abeta